Publications by authors named "Phillip Pymm"

Claim this Profile
E
Elevated SARS-CoV-2 IgG4 in plasma and mucosa following repeated mRNA boosters impact antibody functions to Omicron and sarbecoviruses.
Kevin J Selva, Wen Shi Lee, Alther L Enriquez, L Carissa Aurelia, Jennifer Audsley, Phillip Pymm

EBioMedicine· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel chimeric coronavirus spike vaccine combining SARS-CoV-2 RBD and scaffold domains from HKU-1 elicits potent neutralising antibody responses.
Veronica P Zoest, Wen Shi Lee, Lydia Murdiyarso, Lauren Burmas, Phillip Pymm

NPJ Vaccines· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stabilized designs of the malaria adhesin protein PvRBP2b for use as a potential diagnostic for Plasmodium vivax.
Jaison D Sa, Lucas Krauss, Lauren Smith, Laura D'Andrea, Li-Jin Chan, Phillip Pymm

J Biol Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Structural Basis for Recognition of Human Leukocyte Antigen Class I Molecules by the Pan-HLA Antibody W6/32.
Phillip Pymm, Philippa M Saunders, Sushma Anand, Bruce J MacLachlan, Camilla Faoro

J Immunol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection.
Amy Adair, Li Lynn Tan, Jackson Feng, Jason Girkin, Nathan Bryant, Phillip Pymm

J Virol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants.
Ebene R Haycroft, Samantha K Davis, Pradhipa Ramanathan, Ester Lopez, Ruth A Purcell, Phillip Pymm

Med Microbiol Immunol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2.
Bruce D Wines, Liriye Kurtovic, Halina M Trist, Sandra Esparon, Ester Lopez, Phillip Pymm

Front Immunol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2.
Phillip Pymm, Samuel J Redmond, Olan Dolezal, Francesca Mordant, Ester Lopez

iScience· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma.
Samantha K Davis, Kevin John Selva, Ester Lopez, Ebene R Haycroft, Wen Shi Lee, Phillip Pymm

Clin Transl Immunology· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2.
Bruce D Wines, Liriye Kurtovic, Halina M Trist, Sandra Esparon, Ester Lopez, Phillip Pymm

Front Immunol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epitope length variants balance protective immune responses and viral escape in HIV-1 infection.
Phillip Pymm, Stefan Tenzer, Edmund Wee, Mirjana Weimershaus, Anne Burgevin

Cell Rep· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
Adam K Wheatley, Phillip Pymm, Robyn Esterbauer, Melanie H Dietrich, Wen Shi Lee

Cell Rep· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.
Ester Lopez, Ebene R Haycroft, Amy Adair, Francesca L Mordant, Matthew T O'Neill, Phillip Pymm

JCI Insight· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
Phillip Pymm, Amy Adair, Li-Jin Chan, James P Cooney, Francesca L Mordant

Proc Natl Acad Sci U S A· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural plasticity of KIR2DL2 and KIR2DL3 enables altered docking geometries atop HLA-C.
Shoeib Moradi, Sanda Stankovic, Geraldine M O'Connor, Phillip Pymm, Bruce J MacLachlan

Nat Commun· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanobody generation and structural characterization of Plasmodium falciparum 6-cysteine protein Pf12p.
Melanie H Dietrich, Li-Jin Chan, Amy Adair, Sravya Keremane, Phillip Pymm

Biochem J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19.
Jennifer A Juno, Hyon-Xhi Tan, Wen Shi Lee, Arnold Reynaldi, Hannah G Kelly, Phillip Pymm

Nat Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The molecular basis of how buried human leukocyte antigen polymorphism modulates natural killer cell function.
Philippa M Saunders, Bruce J MacLachlan, Phillip Pymm, Patricia T Illing, Yuanchen Deng

Proc Natl Acad Sci U S A· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Production of Recombinant Killer Immunoglobulin-Like Receptors for Crystallography and Luminex-Based Assays.
Phillip Pymm, Julian P Vivian

Methods Mol Biol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome.
Patricia T Illing, Phillip Pymm, Nathan P Croft, Hugo G Hilton, Vladimir Jojic

Nat Commun· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1.
Maureen P Martin, Vivek Naranbhai, Patrick R Shea, Ying Qi, Veron Ramsuran, Phillip Pymm

J Clin Invest· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape.
Phillip Pymm, Patricia T Illing, Sri H Ramarathinam, Geraldine M O'Connor, Victoria A Hughes

Nat Struct Mol Biol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition.
Philippa M Saunders, Phillip Pymm, Gabriella Pietra, Victoria A Hughes, Corinne Hitchen

J Exp Med· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A bird's eye view of NK cell receptor interactions with their MHC class I ligands.
Philippa M Saunders, Julian P Vivian, Geraldine M O'Connor, Lucy C Sullivan, Phillip Pymm

Immunol Rev· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum for O'Connor et al., Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1.
Geraldine M O'Connor, Julian P Vivian, Emma Gostick, Phillip Pymm, Bernard A P Lafont

J Virol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis